Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial

被引：55

作者：

Baron, Ralf ^{[1
]}

Jansen, Jan-Peter ^{[2
]}

Binder, Andreas ^{[1
]}

Pombo-Suarez, Manuel ^{[3
]}

Kennes, Lieven ^{[4
]}

Mueller, Matthias ^{[5
]}

Falke, Dietmar ^{[5
]}

Steigerwald, Ilona ^{[5
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Neurol, Div Neurol Pain Res & Therapy, Campus Kiel, Kiel, Germany

[2] Pain Ctr, Berlin, Germany

[3] Univ Santiago de Compostela, Clin Univ Hosp, Santiago De Compostela, Spain

[4] Grunenthal GmbH, Grunenthal Innovat Global Biometr, Aachen, Germany

[5] Grunenthal GmbH, Med Affairs Europe & Australia, Aachen, Germany

来源：

PAIN PRACTICE | 2016年 / 16卷 / 05期

关键词：

tolerability; safety; quality of life; tapentadol prolonged release; chronic low back pain; OPIOID-INDUCED CONSTIPATION; INDUCED BOWEL DYSFUNCTION; FORM HEALTH SURVEY; EXTENDED-RELEASE; DOUBLE-BLIND; MANAGEMENT; EFFICACY; MODERATE; PLACEBO; OSTEOARTHRITIS;

D O I：

10.1111/papr.12361

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

ObjectiveTo evaluate tolerability, safety, and quality-of-life outcomes in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic component receiving tapentadol PR vs. oxycodone/naloxone PR. MethodsEligible patients (average pain intensity [numerical rating scale] 6; painDETECT positive/unclear ratings) were randomized to twice-daily tapentadol PR 50 mg or oxycodone/naloxone PR 10 mg/5 mg. After a 21-day titration (maximum twice-daily doses: tapentadol PR 250 mg, or oxycodone/naloxone PR 40 mg/20 mg plus oxycodone PR 10 mg), target doses were continued for 9 weeks. Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) total score from baseline to final evaluation was a primary endpoint. ResultsFor the primary tolerability-related endpoint, the 97.5% exact repeated confidence interval for tapentadol PR minus oxycodone/naloxone PR for the PAC-SYM total score was [-0.259, 0.121], showing noninferiority (upper limit < 0.7). Incidences of constipation and vomiting were significantly lower with tapentadol PR than oxycodone/naloxone PR (P 0.045). Confirmatory superiority based on formal noninferiority was shown for the primary effectiveness endpoint (change from baseline to final evaluation in pain intensity) for tapentadol PR vs. oxycodone/naloxone PR (presented separately). Improvements in the Short Form-12 physical component summary and EuroQol-5 Dimension health status index and health state assessment were significantly greater with tapentadol PR vs. oxycodone/naloxone PR (P 0.024). ConclusionsTapentadol PR had a minimal impact on bowel function (noninferior to oxycodone/naloxone PR) and, along with superior effectiveness (presented separately), was associated with significantly lower incidences of constipation and vomiting and significant improvements in quality-of-life measures vs. oxycodone/naloxone PR.

引用

页码：600 / 619

页数：20

共 26 条

[21] Rationale and Design of a Phase 3b Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Pediatric Patients with Immune Thrombocytopenia
Grace, Rachael F.
Xue, Xiaoqiang
Jamieson, Brian
BLOOD, 2021, 138
[22] HEALTH-RELATED QUALITY OF LIFE OUTCOMES WITH FREMANEZUMAB IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE WHO HAD INADEQUATE RESPONSE TO 2-4 PRIOR MIGRAINE PREVENTIVE MEDICATION CLASSES: OPEN-LABEL EXTENSION OF THE PHASE 3B FOCUS STUDY
Buse, Dawn C.
Ning, Xiaoping
Campos, Verena Ramirez
Cohen, Joshua
Du, Evelyn
Mechtler, Laszlo
CEPHALALGIA, 2020, 40 : 78 - 79
[23] SHORT FORM-36 (SF-36) AND EUROQOL-5 DIMENSION (EQ-5D) RESULTS FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOI. PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN
Lange, R.
Lange, B.
Greene, A.
Okamoto, A.
Etropolski, M.
Ashworth, J.
OSTEOARTHRITIS AND CARTILAGE, 2010, 18 : S147 - S148
[24] A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
Keisha Smith
Amy Pace
Stephan Ortiz
Shamsah Kazani
Scott Rottinghaus
Trials, 21
[25] A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial
Smith, Keisha
Pace, Amy
Ortiz, Stephan
Kazani, Shamsah
Rottinghaus, Scott
TRIALS, 2020, 21 (01)
[26] Efficacy and Safety of Low-Dose Transdermal Buprenorphine Patches (5, 10, and 20 μg/h) Versus Prolonged-Release Tramadol Tablets (75, 100, 150, and 200 mg) in Patients With Chronic Osteoarthritis Pain: A 12-Week, Randomized, Open-Label, Controlled, Parallel-Group Noninferiority Study
Karlsson, Mats
Berggren, Anna-Carin
CLINICAL THERAPEUTICS, 2009, 31 (03) : 503 - 513

← 1 2 3 →